These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

329 related articles for article (PubMed ID: 32147909)

  • 1. Analysis of DNA methylation patterns in the tumor immune microenvironment of metastatic melanoma.
    Mitra S; Lauss M; Cabrita R; Choi J; Zhang T; Isaksson K; Olsson H; Ingvar C; Carneiro A; Staaf J; Ringnér M; Nielsen K; Brown KM; Jönsson G
    Mol Oncol; 2020 May; 14(5):933-950. PubMed ID: 32147909
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Genome-wide methylation sequencing of paired primary and metastatic cell lines identifies common DNA methylation changes and a role for EBF3 as a candidate epigenetic driver of melanoma metastasis.
    Chatterjee A; Stockwell PA; Ahn A; Rodger EJ; Leichter AL; Eccles MR
    Oncotarget; 2017 Jan; 8(4):6085-6101. PubMed ID: 28030832
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Promoter Methylation of PTEN Is a Significant Prognostic Factor in Melanoma Survival.
    Roh MR; Gupta S; Park KH; Chung KY; Lauss M; Flaherty KT; Jönsson G; Rha SY; Tsao H
    J Invest Dermatol; 2016 May; 136(5):1002-1011. PubMed ID: 26854490
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Data mining of immune-related prognostic genes in metastatic melanoma microenvironment.
    Han W; Huang B; Zhao XY; Shen GL
    Biosci Rep; 2020 Nov; 40(11):. PubMed ID: 33169786
    [TBL] [Abstract][Full Text] [Related]  

  • 5. BRN2 is a non-canonical melanoma tumor-suppressor.
    Hamm M; Sohier P; Petit V; Raymond JH; Delmas V; Le Coz M; Gesbert F; Kenny C; Aktary Z; Pouteaux M; Rambow F; Sarasin A; Charoenchon N; Bellacosa A; Sanchez-Del-Campo L; Mosteo L; Lauss M; Meijer D; Steingrimsson E; Jönsson GB; Cornell RA; Davidson I; Goding CR; Larue L
    Nat Commun; 2021 Jun; 12(1):3707. PubMed ID: 34140478
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Epigenetic inactivation of RAS association domain family protein 1 (RASSF1A) in malignant cutaneous melanoma.
    Spugnardi M; Tommasi S; Dammann R; Pfeifer GP; Hoon DS
    Cancer Res; 2003 Apr; 63(7):1639-43. PubMed ID: 12670917
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A novel hypoxia-associated subset of FN1 high MITF low melanoma cells: identification, characterization, and prognostic value.
    Wouters J; Stas M; Govaere O; Barrette K; Dudek A; Vankelecom H; Haydu LE; Thompson JF; Scolyer RA; van den Oord JJ
    Mod Pathol; 2014 Aug; 27(8):1088-100. PubMed ID: 24390218
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Topological Tumor Graphs: A Graph-Based Spatial Model to Infer Stromal Recruitment for Immunosuppression in Melanoma Histology.
    Failmezger H; Muralidhar S; Rullan A; de Andrea CE; Sahai E; Yuan Y
    Cancer Res; 2020 Mar; 80(5):1199-1209. PubMed ID: 31874858
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Genome-wide DNA methylation profile identified a unique set of differentially methylated immune genes in oral squamous cell carcinoma patients in India.
    Basu B; Chakraborty J; Chandra A; Katarkar A; Baldevbhai JRK; Dhar Chowdhury D; Ray JG; Chaudhuri K; Chatterjee R
    Clin Epigenetics; 2017; 9():13. PubMed ID: 28174608
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification of novel epigenetically modified genes in human melanoma via promoter methylation gene profiling.
    Liu S; Ren S; Howell P; Fodstad O; Riker AI
    Pigment Cell Melanoma Res; 2008 Oct; 21(5):545-58. PubMed ID: 18627528
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Methylation of PTEN as a prognostic factor in malignant melanoma of the skin.
    Lahtz C; Stranzenbach R; Fiedler E; Helmbold P; Dammann RH
    J Invest Dermatol; 2010 Feb; 130(2):620-2. PubMed ID: 19798057
    [No Abstract]   [Full Text] [Related]  

  • 12. Molecular, clinicopathological, and immune correlates of LAG3 promoter DNA methylation in melanoma.
    Fröhlich A; Sirokay J; Fietz S; Vogt TJ; Dietrich J; Zarbl R; Florin M; Kuster P; Saavedra G; Valladolid SR; Hoffmann F; Flatz L; Ring SS; Golletz C; Pietsch T; Strieth S; Brossart P; Gielen GH; Kristiansen G; Bootz F; Landsberg J; Dietrich D
    EBioMedicine; 2020 Sep; 59():102962. PubMed ID: 32861198
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molecular and epigenetic features of melanomas and tumor immune microenvironment linked to durable remission to ipilimumab-based immunotherapy in metastatic patients.
    Seremet T; Koch A; Jansen Y; Schreuer M; Wilgenhof S; Del Marmol V; Liènard D; Thielemans K; Schats K; Kockx M; Van Criekinge W; Coulie PG; De Meyer T; van Baren N; Neyns B
    J Transl Med; 2016 Aug; 14(1):232. PubMed ID: 27484791
    [TBL] [Abstract][Full Text] [Related]  

  • 14. DNA hypermethylation is associated with invasive phenotype of malignant melanoma.
    Koroknai V; Szász I; Hernandez-Vargas H; Fernandez-Jimenez N; Cuenin C; Herceg Z; Vízkeleti L; Ádány R; Ecsedi S; Balázs M
    Exp Dermatol; 2020 Jan; 29(1):39-50. PubMed ID: 31602702
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Genome-Wide DNA Methylation Analysis in Melanoma Reveals the Importance of CpG Methylation in MITF Regulation.
    Lauss M; Haq R; Cirenajwis H; Phung B; Harbst K; Staaf J; Rosengren F; Holm K; Aine M; Jirström K; Borg Å; Busch C; Geisler J; Lønning PE; Ringnér M; Howlin J; Fisher DE; Jönsson G
    J Invest Dermatol; 2015 Jul; 135(7):1820-1828. PubMed ID: 25705847
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Aberrant DNA methylation is associated with aggressive clinicopathological features and poor survival in cutaneous melanoma.
    de Unamuno Bustos B; Murria Estal R; Pérez Simó G; Simarro Farinos J; Pujol Marco C; Navarro Mira M; Alegre de Miquel V; Ballester Sánchez R; Sabater Marco V; Llavador Ros M; Palanca Suela S; Botella Estrada R
    Br J Dermatol; 2018 Aug; 179(2):394-404. PubMed ID: 29278418
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High-frequency p16(INK) (4A) promoter methylation is associated with histone methyltransferase SETDB1 expression in sporadic cutaneous melanoma.
    Kostaki M; Manona AD; Stavraka I; Korkolopoulou P; Levidou G; Trigka EA; Christofidou E; Champsas G; Stratigos AJ; Katsambas A; Papadopoulos O; Piperi C; Papavassiliou AG
    Exp Dermatol; 2014 May; 23(5):332-8. PubMed ID: 24673285
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Epigenome-wide DNA methylation landscape of melanoma progression to brain metastasis reveals aberrations on homeobox D cluster associated with prognosis.
    Marzese DM; Scolyer RA; Huynh JL; Huang SK; Hirose H; Chong KK; Kiyohara E; Wang J; Kawas NP; Donovan NC; Hata K; Wilmott JS; Murali R; Buckland ME; Shivalingam B; Thompson JF; Morton DL; Kelly DF; Hoon DS
    Hum Mol Genet; 2014 Jan; 23(1):226-38. PubMed ID: 24014427
    [TBL] [Abstract][Full Text] [Related]  

  • 19. DNA methylation variations of DNA damage response correlate survival and local immune status in melanomas.
    Wang M; Zhang XD; Yang HQ; Li Y; Chen WM; Yin AA
    Immun Inflamm Dis; 2024 Sep; 12(9):e1331. PubMed ID: 39254643
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunotype and immunohistologic characteristics of tumor-infiltrating immune cells are associated with clinical outcome in metastatic melanoma.
    Erdag G; Schaefer JT; Smolkin ME; Deacon DH; Shea SM; Dengel LT; Patterson JW; Slingluff CL
    Cancer Res; 2012 Mar; 72(5):1070-80. PubMed ID: 22266112
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.